Given the synergism seen between PI3K inhibitors and rapamycin in lung cancer cell lines, a dual PI3K/mTOR inhibitor that has been given to solid tumor patients in phase I clinical trials, NVP-BEZ235, was studied. The gene discussed is MTOR; the disease is lung carcinoma.